Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ayesha Khan, Anne Corbett & Clive Ballard. (2017) Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets. Expert Review of Neurotherapeutics 17:7, pages 683-695.
Read now
Read now
Articles from other publishers (38)
Lei Zheng & Zhong-Zhen Zhou. (2023) An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential. European Journal of Medicinal Chemistry 259, pages 115682.
Crossref
Crossref
Anna Mathew, Vignesh Balaji E, Sreedhara Ranganath K. Pai, Anoop Kishore, Vasudev Pai, Ramadevi Pemmireddy & Chandrashekar K.S. (2023) Current Drug Targets in Alzheimer’s Associated Memory Impairment: A
Comprehensive Review. CNS & Neurological Disorders - Drug Targets 22:2, pages 255-275.
Crossref
Crossref
Laura Elisabeth Rosalie Blok, Marina Boon, Boyd van Reijmersdal, Kira Daniela Höffler, Michaela Fenckova & Annette Schenck. (2022) Genetics, molecular control and clinical relevance of habituation learning. Neuroscience & Biobehavioral Reviews 143, pages 104883.
Crossref
Crossref
Maria Rosaria Tropea, Walter Gulisano, Valeria Vacanti, Ottavio Arancio, Daniela Puzzo & Agostino Palmeri. (2022) Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's disease. Free Radical Biology and Medicine 193, pages 657-668.
Crossref
Crossref
Ai Jiang, Margrate Anyanwu, Kafai Leong, Jinxin Li, Alessandra Gianoncelli, Paolo Coghi & Giovanni Ribaudo. (2022) 3-[(1H-Benzo[d][1,2,3]triazol-1-yl)oxy]propyl 9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylate. Molbank 2022:3, pages M1419.
Crossref
Crossref
Jia-yi You, Xin-wei Liu, Ying-xia Bao, Zheng-nan Shen, Quan Wang, Gong-yun He, Jing Lu, Ji-guo Zhang, Jian-wen Chen & Pei-qing Liu. (2022) A novel phosphodiesterase 9A inhibitor LW33 protects against ischemic stroke through the cGMP/PKG/CREB pathway. European Journal of Pharmacology 925, pages 174987.
Crossref
Crossref
Meiyang Xi, Tianyu Sun, Shejie Chai, Mengjiao Xie, Siqi Chen, Liping Deng, Kui Du, Runpu Shen & Haopeng Sun. (2022) Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease. European Journal of Medicinal Chemistry 232, pages 114170.
Crossref
Crossref
Mohammad Nasiruddin Rana, Jie Lu, Enfu Xue, Jingjing Ruan, Yuting Liu, Lejun Zhang, Rana Dhar, Yajun Li, Zhengqiang Hu, Jie Zhou, Wangqian Ma & Huifang Tang. (2021) PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization. Frontiers in Pharmacology 12.
Crossref
Crossref
Elentina K. Argyrousi, Pim R.A. Heckman & Jos Prickaerts. (2020) Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot. Neuroscience & Biobehavioral Reviews 113, pages 12-38.
Crossref
Crossref
John F. Harms, Frank S. Menniti & Christopher J. Schmidt. (2019) Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide. Frontiers in Neuroscience 13.
Crossref
Crossref
Robert J. Charnigo, David Beidler, Denis Rybin, Debra D. Pittman, Beesan Tan, Jo Howard, Alan D. Michelson, Andrew L. Frelinger, III, III & Nicholas Clarke. (2018)
PF
‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study
. Clinical and Translational Science 12:2, pages 180-188.
Crossref
Crossref
Michael A. Hollas, Manel Ben Aissa, Sue H. Lee, Jesse M. Gordon-Blake & Gregory R.J. Thatcher. (2019) Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery. Nitric Oxide 82, pages 59-74.
Crossref
Crossref
Xian-Feng Huang, Wen-Tao Jiang, Li Liu, Fang-Chen Song, Xia Zhu, Gui-Lan Shi, Shu-Ming Ding, Heng-Ming Ke, Wei Wang, James M. O'Donnell, Han-Ting Zhang, Hai-Bin Luo, Yi-Qian Wan, Guo-Qiang Song & Ying Xu. (2018) A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling. CNS Neuroscience & Therapeutics 24:10, pages 889-896.
Crossref
Crossref
Yinuo Wu, Zhe Li, Yi-You Huang, Deyan Wu & Hai-Bin Luo. (2018) Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease. Journal of Medicinal Chemistry 61:13, pages 5467-5483.
Crossref
Crossref
Austin Horton, Kevin Nash, Ethel Tackie-Yarboi, Alexander Kostrevski, Adam Novak, Aparna Raghavan, Jatin Tulsulkar, Qasim Alhadidi, Nathan Wamer, Bryn Langenderfer, Kalee Royster, Maxwell Ducharme, Katelyn Hagood, Megan Post, Zahoor A. Shah & Isaac T. Schiefer. (2018)
Furoxans (Oxadiazole-4
N
-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory
. Journal of Medicinal Chemistry 61:10, pages 4593-4607.
Crossref
Crossref
P.R.A. Heckman, A. Blokland, E.P.P. Bollen & J. Prickaerts. (2018) Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. Neuroscience & Biobehavioral Reviews 87, pages 233-254.
Crossref
Crossref
Kristen Kokkonen & David A. Kass. (2017) Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. Annual Review of Pharmacology and Toxicology 57:1, pages 455-479.
Crossref
Crossref
P.H. HutsonJ.A. ClarkA.J. Cross. (2017) CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?. Annual Review of Pharmacology and Toxicology 57:1, pages 171-187.
Crossref
Crossref
C. Dorner-Ciossek, K. S. Kroker & H. Rosenbrock. 2017. Phosphodiesterases: CNS Functions and Diseases. Phosphodiesterases: CNS Functions and Diseases
231
254
.
Pim R. A. Heckman, Arjan Blokland & Jos Prickaerts. 2017. Phosphodiesterases: CNS Functions and Diseases. Phosphodiesterases: CNS Functions and Diseases
135
168
.
M S Alexander, M J Gasperini, P T Tsai, D E Gibbs, J M Spinazzola, J L Marshall, M J Feyder, M T Pletcher, E L P Chekler, C A Morris, M Sahin, J F Harms, C J Schmidt, R J Kleiman & L M Kunkel. (2016) Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A. Translational Psychiatry 6:9, pages e901-e901.
Crossref
Crossref
Jian Li, Chun-Na Liu, Ning Wei, Xi-Dong Li, Yuan-Yuan Liu, Rui Yang & Yu-Jie Jia. (2016) Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease. Brain Research 1642, pages 327-335.
Crossref
Crossref
M. Huang, Y. Shao, J. Hou, W. Cui, B. Liang, Y. Huang, Z. Li, Y. Wu, X. Zhu, P. Liu, Y. Wan, H. Ke & H.-B. Luo. (2015) Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor. Molecular Pharmacology 88:5, pages 836-845.
Crossref
Crossref
Roland Seifert, Erich H. Schneider & Heike Bähre. (2015) From canonical to non-canonical cyclic nucleotides as second messengers: Pharmacological implications. Pharmacology & Therapeutics 148, pages 154-184.
Crossref
Crossref
P.R.A. Heckman, A. Blokland, J. Ramaekers & J. Prickaerts. (2015) PDE and cognitive processing: Beyond the memory domain. Neurobiology of Learning and Memory 119, pages 108-122.
Crossref
Crossref
Dávid Nagy, Francis D. TingleyIIIIII, Milan Stoiljkovic & Mihály Hajós. (2015) Application of neurophysiological biomarkers for Huntington's disease: Evaluating a phosphodiesterase 9A inhibitor. Experimental Neurology 263, pages 122-131.
Crossref
Crossref
Yong-xian Shao, Manna Huang, Wenjun Cui, Ling-Jun Feng, Yinuo Wu, Yinghong Cai, Zhe Li, Xinhai Zhu, Peiqing Liu, Yiqian Wan, Hengming Ke & Hai-Bin Luo. (2014) Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent. Journal of Medicinal Chemistry 57:24, pages 10304-10313.
Crossref
Crossref
Nivedita Singh & Sanjukta Patra. (2014) Phosphodiesterase 9: Insights from protein structure and role in therapeutics. Life Sciences 106:1-2, pages 1-11.
Crossref
Crossref
Han-Ting Zhang, Ying Xu & James O'Donnell. 2014. Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System. Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System
171
210
.
Marco Conti & Wito Richter. 2014. Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System. Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System
1
46
.
Jamison B. Tuttle & Bethany L. Kormos. 2015. Small Molecule Therapeutics for Schizophrenia. Small Molecule Therapeutics for Schizophrenia
255
316
.
Qin Zhihui. (2013) Modulating nitric oxide signaling in the CNS for Alzheimer’s disease therapy. Future Medicinal Chemistry 5:12, pages 1451-1468.
Crossref
Crossref
Ana García-Osta, Mar Cuadrado-Tejedor, Carolina García-Barroso, Julen Oyarzábal & Rafael Franco. (2012) Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. ACS Chemical Neuroscience 3:11, pages 832-844.
Crossref
Crossref
Michelle M. Claffey, Christopher J. Helal, Patrick R. Verhoest, Zhijun Kang, Kristina S. Fors, Stanley Jung, Jiaying Zhong, Mark W. Bundesmann, Xinjun Hou, Shenping Lui, Robin J. Kleiman, Michelle Vanase-Frawley, Anne W. Schmidt, Frank Menniti, Christopher J. Schmidt, William E. Hoffman, Mihaly Hajos, Laura McDowell, Rebecca E. O’Connor, Mary MacDougall-Murphy, Kari R. Fonseca, Stacey L. Becker, Frederick R. Nelson & Spiros Liras. (2012) Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors. Journal of Medicinal Chemistry 55:21, pages 9055-9068.
Crossref
Crossref
Patrick R. Verhoest, Kari R. Fonseca, Xinjun Hou, Caroline Proulx-LaFrance, Michael Corman, Christopher J. Helal, Michelle M. Claffey, Jamison B. Tuttle, Karen J. Coffman, Shenpinq Liu, Frederick Nelson, Robin J. Kleiman, Frank S. Menniti, Christopher J. Schmidt, Michelle Vanase-Frawley & Spiros Liras. (2012)
Design and Discovery of 6-[(3
S
,4
S
)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2
H
-pyran-4-yl)-1,5-dihydro-4
H
-pyrazolo[3,4-
d
]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders
. Journal of Medicinal Chemistry 55:21, pages 9045-9054.
Crossref
Crossref
Fei Meng, Jing Hou, Yong-Xian Shao, Pei-Ying Wu, Manna Huang, Xinhai Zhu, Yonghong Cai, Zhe Li, Jie Xu, Peiqing Liu, Hai-Bin Luo, Yiqian Wan & Hengming Ke. (2012) Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design. Journal of Medicinal Chemistry 55:19, pages 8549-8558.
Crossref
Crossref
Robin J. Kleiman, Douglas S. Chapin, Curt Christoffersen, Jody Freeman, Kari R. Fonseca, Kieran F. Geoghegan, Sarah Grimwood, Victor Guanowsky, Mihály Hajós, John F. Harms, Christopher J. Helal, William E. Hoffmann, Geralyn P. Kocan, Mark J. Majchrzak, Dina McGinnis, Stafford McLean, Frank S. Menniti, Fredrick Nelson, Robin Roof, Anne W. Schmidt, Patricia A. Seymour, Diane T. Stephenson, Francis David Tingley, Michelle Vanase-Frawley, Patrick R. Verhoest & Christopher J. Schmidt. (2012) Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo. Journal of Pharmacology and Experimental Therapeutics 341:2, pages 396-409.
Crossref
Crossref
Sharma A, Goyal A & Garabadu D. (2019) Phosphodiesterase Inhibitors: A Therapeutic Augmentation for Treatment of Cognitive Impairment. SSRN Electronic Journal.
Crossref
Crossref